AKBA
Akebia Therapeutics, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Sell
-40/100
Last price
0.88
▼ 0.03 (3.08%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
0.90
Prev close
0.91
Day high
0.91
Day low
0.88
Volume
6.18M
Market cap
$243.44M
P/E (TTM)
—
52W range
0.81 – 3.20
Day trading desk
Gap from prior close
-0.76%
Prior close 0.91
VWAP
0.88
-0.13% from price
Relative volume
2.00×
Unusually busy
Session range
4.00%
0.88 – 0.91
Position in range
21%
Near session low
ATR (14D)
0.05
5.41% of price
Prior day high
0.92
PDH
Prior day low
0.85
PDL
Bid / ask spread
—
Quote not published
Session volume
12.21M
Avg 6.09M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-0.79%
-2.7%
1M
-9.85%
-11.0%
3M
-38.10%
-42.6%
6M
-36.30%
-54.5%
YTD
-45.40%
-59.7%
1Y
-68.94%
-85.4%
3Y
-22.89%
-105.1%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on AKBA open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+508.18K
Net buying
Buy transactions
7
564.20K shares
Sell transactions
1
56.02K shares
Net transactions
+8
Buys less sells
Sell : buy shares
0.1 : 1
Mixed
Insider-held shares
5.49M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 6, 26 | BUTLER JOHN P Chief Executive Officer |
CONVERSION | 350.00K | $220.50K | Direct |
| Jun 29, 26 | OSTROWSKI ERIK Chief Financial Officer |
SELL | 56.02K | $62.18K | Direct |
| Jun 17, 26 | WOLF MYLES Director |
STOCK | 35.70K | $0 | Direct |
| Jun 17, 26 | FRIESON RON Director |
STOCK | 35.70K | $0 | Direct |
| Jun 17, 26 | ROGERS MICHAEL W Director |
STOCK | 35.70K | $0 | Direct |
| Jun 17, 26 | ADAMS ADRIAN Director |
STOCK | 35.70K | $0 | Direct |
| Jun 17, 26 | ZUMWALT LEANNE M Director |
STOCK | 35.70K | $0 | Direct |
| Jun 17, 26 | SMITH CYNTHIA Director |
STOCK | 35.70K | $0 | Direct |
| Mar 4, 26 | BUTLER JOHN P Chief Executive Officer |
BUY | 69.27K | $86.59K | Direct |
| Feb 2, 26 | BURKE STEVEN KEITH Officer |
SELL | 67.66K | $94.05K | Direct |
| Feb 2, 26 | BUTLER JOHN P Chief Executive Officer |
SELL | 341.31K | $474.41K | Direct |
| Feb 2, 26 | GRUND NICHOLAS Officer |
SELL | 84.83K | $117.91K | Direct |
| Feb 2, 26 | OSTROWSKI ERIK Chairman of the Board |
SELL | 34.95K | $48.58K | Direct |
| Feb 2, 26 | MALABRE RICHARD C. Officer |
SELL | 49.52K | $68.84K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ADAMS ADRIAN |
Director | 236.20K | Stock Award(Grant) |
BURKE STEVEN KEITH |
Officer | 948.43K | Sale |
BUTLER JOHN P |
Chief Executive Officer | 3.88M | Conversion of Exercise of derivative security |
GRUND NICHOLAS |
Officer | 561.75K | Sale |
MALABRE RICHARD C. |
Officer | 299.39K | Sale |
OSTROWSKI ERIK |
Chief Financial Officer | 616.62K | Sale |
ROGERS MICHAEL W |
Director | 197.43K | Stock Award(Grant) |
RUCCI CAROLYN M |
Officer | 588.38K | Sale |
SMITH CYNTHIA |
Director | 196.63K | Stock Award(Grant) |
WOLF MYLES |
Director | 169.08K | Stock Award(Grant) |
Fundamentals
Market cap$243.44M
Enterprise value$287.08M
Revenue (TTM)$219.06M
Gross profit$178.40M
EBITDA$-4.30M
Net income$-29.67M
EPS (TTM)$-0.13
Free cash flow$33.64M
Total cash$155.55M
Total debt$199.19M
Book value / share$0.09
Shares outstanding277.11M
Float272.25M
Short % of float7.51%
Dividend yield0.00%
Beta (5Y)0.18
Valuation & profitability ratios
Trailing P/E—
Forward P/E-2.44
PEG ratio—
Price / sales—
Price / book9.55
EV / revenue1.31
EV / EBITDA-66.82
Gross margin81.44%
Operating margin-5.46%
Profit margin-13.54%
Return on equity-109.38%
Return on assets-1.05%
Debt / equity796.18
Current ratio1.43
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $236.20M | $160.18M | $194.62M | $292.48M | +47.5% |
| Operating revenue | $236.20M | $160.18M | $194.62M | $292.48M | +47.5% |
| Cost of revenue | $39.46M | $63.18M | $74.15M | $85.57M | -37.5% |
| Gross profit | $196.73M | $97.00M | $120.47M | $206.92M | +102.8% |
| Research & development | $62.36M | $37.65M | $63.08M | $129.99M | +65.6% |
| Selling, general & admin | $107.48M | $106.55M | $100.23M | $138.60M | +0.9% |
| Total operating expense | $173.24M | $147.42M | $166.55M | $271.76M | +17.5% |
| Operating income | $23.50M | -$50.41M | -$46.08M | -$64.85M | +146.6% |
| Net interest income | -$24.18M | -$18.18M | -$6.03M | -$15.69M | -33.0% |
| Pre-tax income | -$3.72M | -$69.41M | -$51.92M | -$94.23M | +94.6% |
| Tax provision | $1.62M | $0 | $0 | $0 | — |
| Net income | -$5.34M | -$69.41M | -$51.92M | -$94.23M | +92.3% |
| Net income to common | -$5.34M | -$69.41M | -$51.92M | -$94.23M | +92.3% |
| Basic EPS | -0.02 | -0.33 | -0.28 | -0.51 | +93.9% |
| Diluted EPS | -0.02 | -0.33 | -0.28 | -0.51 | +93.9% |
| EBIT | $20.46M | -$51.23M | -$45.89M | -$78.54M | +139.9% |
| EBITDA | $21.73M | -$13.72M | -$8.27M | -$40.84M | +258.3% |
| Basic shares | 257.16M | 210.95M | 187.47M | 182.78M | +21.9% |
| Diluted shares | 257.16M | 210.95M | 187.47M | 182.78M | +21.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $184.84M | $51.87M | $42.92M | $90.47M | — | +256.4% |
| Cash & short-term investments | $184.84M | $51.87M | $42.92M | $90.47M | — | +256.4% |
| Accounts receivable | $47.03M | $34.37M | $39.29M | $40.28M | — | +36.8% |
| Inventory | $15.61M | $16.24M | $15.69M | $21.57M | — | -3.9% |
| Total current assets | $252.96M | $113.83M | $118.15M | $185.18M | — | +122.2% |
| Property, plant & equipment | $4.88M | $10.42M | $16.05M | $34.37M | — | -53.1% |
| Goodwill & intangibles | $59.04M | $59.04M | $95.09M | $131.13M | — | 0.0% |
| Total assets | $376.56M | $220.67M | $241.70M | $356.05M | — | +70.6% |
| Total current liabilities | $162.94M | $80.91M | $99.87M | $129.54M | — | +101.4% |
| Current debt | — | — | $17.50M | $32.00M | $97.54M | — |
| Long-term debt | $48.25M | $38.69M | $17.18M | $34.08M | — | +24.7% |
| Total debt | $51.80M | $47.64M | $48.12M | $99.78M | — | +8.7% |
| Total liabilities | $343.95M | $269.86M | $272.29M | $350.82M | — | +27.5% |
| Retained earnings | -$1.68B | -$1.68B | -$1.61B | -$1.56B | — | -0.3% |
| Shareholder equity | $32.61M | -$49.19M | -$30.58M | $5.23M | — | +166.3% |
| Working capital | $90.02M | $32.92M | $18.28M | $55.65M | — | +173.5% |
| Net tangible assets | -$26.43M | -$108.23M | -$125.67M | -$125.90M | — | +75.6% |
| Shares issued | 265.42M | 224.85M | 194.58M | 184.14M | — | +18.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$5.34M | -$69.41M | -$51.92M | -$94.23M | — | +92.3% |
| Depreciation & amortisation | $1.27M | $37.50M | $37.63M | $37.70M | — | -96.6% |
| Stock-based compensation | $11.28M | $7.78M | $9.32M | $17.85M | — | +45.1% |
| Change in working capital | $16.47M | -$39.68M | -$20.73M | -$1.44M | — | +141.5% |
| Operating cash flow | $67.99M | -$40.66M | -$23.38M | -$73.15M | — | +267.2% |
| Capital expenditure | -$8.10M | -$33.00K | — | -$114.00K | -$59.00K | -24,439.4% |
| Investing cash flow | -$7.93M | -$33.00K | $0 | -$114.00K | — | -23,918.2% |
| Share buybacks | — | -$1.27M | $0 | — | $0 | — |
| Financing cash flow | $72.93M | $49.66M | -$25.21M | $14.60M | — | +46.8% |
| Free cash flow | $59.89M | -$40.69M | -$23.38M | -$73.27M | — | +247.2% |
| End cash position | $186.54M | $53.55M | $44.58M | $93.17M | — | +248.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $49.13M | $53.54M | $57.62M | $58.77M | $62.47M | -8.2% |
| Operating revenue | $49.13M | $53.54M | $57.62M | $58.77M | $62.47M | -8.2% |
| Cost of revenue | $10.42M | $12.29M | $12.54M | $9.38M | $9.92M | -15.2% |
| Gross profit | $38.70M | $41.25M | $45.09M | $49.38M | $52.55M | -6.2% |
| Research & development | $14.06M | $14.81M | $26.65M | $14.94M | $11.01M | -5.1% |
| Selling, general & admin | $28.17M | $30.44M | $26.09M | $29.09M | $26.55M | -7.4% |
| Total operating expense | $43.09M | $45.95M | $53.64M | $44.93M | $38.46M | -6.2% |
| Operating income | -$4.38M | -$4.70M | -$8.55M | $4.45M | $14.09M | +6.7% |
| Net interest income | -$3.07M | -$4.69M | -$4.83M | -$4.75M | -$6.83M | +34.5% |
| Pre-tax income | -$8.84M | -$8.93M | -$11.23M | $1.16M | $247.00K | +1.0% |
| Tax provision | $70.00K | $126.00K | $1.01M | $615.00K | $0 | -44.4% |
| Net income | -$8.91M | -$9.05M | -$12.24M | $540.00K | $247.00K | +1.6% |
| Net income to common | -$8.91M | -$9.05M | -$12.24M | $540.00K | $247.00K | +1.6% |
| Basic EPS | -0.03 | -0.03 | -0.05 | 0.00 | 0.00 | 0.0% |
| Diluted EPS | -0.03 | -0.03 | -0.05 | 0.00 | 0.00 | 0.0% |
| EBIT | -$5.77M | -$4.24M | -$6.41M | $5.90M | $7.08M | -36.1% |
| EBITDA | -$5.18M | -$3.91M | -$6.09M | $6.22M | $7.40M | -32.6% |
| Basic shares | 269.60M | 267.05M | 265.37M | 264.79M | 262.57M | +1.0% |
| Diluted shares | 269.60M | 267.05M | 265.37M | 274.37M | 271.10M | +1.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $155.55M | $162.64M | $184.84M | $166.44M | $137.31M | -4.4% |
| Cash & short-term investments | $155.55M | $162.64M | $184.84M | $166.44M | $137.31M | -4.4% |
| Accounts receivable | $53.51M | $62.54M | $47.03M | $66.22M | $72.81M | -14.4% |
| Inventory | $13.02M | $13.00M | $15.61M | $18.64M | $16.71M | +0.2% |
| Total current assets | $229.55M | $243.48M | $252.96M | $258.34M | $234.66M | -5.7% |
| Property, plant & equipment | $7.31M | $3.42M | $4.88M | $6.31M | $7.70M | +113.8% |
| Goodwill & intangibles | $59.04M | $59.04M | $59.04M | $59.04M | $59.04M | 0.0% |
| Total assets | $349.66M | $362.52M | $376.56M | $364.15M | $345.60M | -3.5% |
| Total current liabilities | $160.87M | $173.88M | $162.94M | $133.38M | $118.72M | -7.5% |
| Current debt | $24.81M | $12.49M | — | — | — | +98.6% |
| Long-term debt | $24.75M | $36.40M | $48.25M | $47.64M | $47.06M | -32.0% |
| Total debt | $54.97M | $51.02M | $51.80M | $52.58M | $53.36M | +7.7% |
| Total liabilities | $324.64M | $335.14M | $343.95M | $322.56M | $316.37M | -3.1% |
| Retained earnings | -$1.70B | -$1.69B | -$1.68B | -$1.67B | -$1.67B | -0.5% |
| Shareholder equity | $25.02M | $27.38M | $32.61M | $41.59M | $29.22M | -8.6% |
| Working capital | $68.69M | $69.60M | $90.02M | $124.96M | $115.94M | -1.3% |
| Net tangible assets | -$34.03M | -$31.67M | -$26.43M | -$17.45M | -$29.82M | -7.4% |
| Shares issued | 271.74M | 267.90M | 265.42M | 265.23M | 263.04M | +1.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$8.91M | -$9.05M | -$12.24M | $540.00K | $247.00K | — | +1.6% |
| Depreciation & amortisation | $585.00K | $328.00K | $321.00K | $318.00K | $316.00K | — | +78.4% |
| Stock-based compensation | $3.23M | $3.67M | $3.20M | $3.22M | $2.68M | — | -12.1% |
| Change in working capital | $3.77M | -$24.54M | $21.87M | $19.23M | $5.10M | — | +115.4% |
| Operating cash flow | $3.52M | -$21.21M | $31.13M | $28.11M | $22.34M | — | +116.6% |
| Capital expenditure | -$4.08M | -$62.00K | -$7.88M | -$77.00K | -$126.00K | — | -6,479.0% |
| Investing cash flow | -$4.08M | -$62.00K | -$7.88M | -$77.00K | -$126.00K | — | -6,479.0% |
| Share buybacks | — | $0 | — | — | — | -$63.00K | — |
| Financing cash flow | -$6.54M | -$926.00K | -$4.85M | $1.11M | $1.72M | — | -606.0% |
| Free cash flow | -$554.00K | -$21.27M | $23.25M | $28.03M | $22.22M | — | +97.4% |
| End cash position | $157.26M | $164.35M | $186.54M | $168.14M | $139.00M | — | -4.3% |
Options analytics
Put / call volume
0.35
Call-heavy session
Put / call open interest
0.26
Positioning, not flow
Max pain
2.00
+127.7% from spot
ATM implied vol
25.0%
Nearest strike to spot
Skew (10% OTM)
-25.0%
Calls bid over puts
Call volume
74
Contracts, this expiry
Put volume
26
Contracts, this expiry
Heaviest call OI
2.00
117 contracts
Heaviest put OI
0.50
22 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.03 | -0.03 | -3.2% |
| Mar 2026 | -0.02 | -0.03 | -50.0% |
| Dec 2025 | -0.06 | -0.05 | +16.7% |
| Sep 2025 | -0.01 | 0.00 | +100.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.03 | 2 | $46.94M | -20.1% |
| Next quarter | -0.03 | 2 | $48.19M | -16.4% |
| Current year | -0.16 | 1 | $197.85M | -16.2% |
| Next year | -0.36 | 2 | $132.51M | -33.0% |
Analyst targets & ownership
Mean target$3.92
High target$6.00
Low target$1.00
Implied upside343.82%
Analyst count6
ConsensusNONE
Strong buy / Buy1 / 4
Hold1
Sell / Strong sell0 / 0
Held by insiders1.98%
Held by institutions40.77%
Institutions holding223
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
0.90
-1.65% from price
SMA 20
0.92
-4.15% from price
SMA 50
0.97
-9.40% from price
SMA 100
1.05
-15.71% from price
SMA 200
1.22
-28.18% from price
EMA 12
0.90
-2.10% from price
EMA 26
0.93
-4.67% from price
EMA 50
0.97
-9.44% from price
RSI (14)
43.5
Neutral
MACD (12,26,9)
-0.02
Hist 0.00
ATR (14)
0.05
5.44% of price
Realised vol 30D
61.8%
Annualised
Bollinger upper
0.98
20, 2σ
Bollinger lower
0.86
20, 2σ
50 / 200 cross
Death
0.97 vs 1.22
Trend bias
Below 200
-28.18%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.11
More volatile than market
Correlation to SPY
0.19
Largely independent
Realised vol 30D
61.8%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-73.4%
Peak to trough
Max drawdown 5Y
-92.5%
Peak to trough
ATR 14
0.05
5.44% of price
Beta (reported)
0.18
5Y monthly, from filing
Short interest
Shares short
20.50M
Prior 21.37M
Change vs prior
-4.1%
Shorts covering
% of float
7.51%
Normal
% of shares out
7.40%
Against total outstanding
Days to cover
2.4
Liquid
Float
272.25M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 15, 26 | BTIG | MAINTAINED | Buy | Buy |
| Sep 8, 26 | WestPark Capital | INITIATED | — | Buy |
| Aug 8, 26 | Leerink Partners | DOWNGRADE | Outperform | Market Perform |
| Jul 1, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 7, 26 | BTIG | MAINTAINED | Buy | Buy |
| Feb 25, 26 | BTIG | MAINTAINED | Buy | Buy |
| Feb 6, 26 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Feb 6, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Dec 2, 25 | BTIG | MAINTAINED | Buy | Buy |
| Dec 2, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Oct 30, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Oct 29, 25 | BTIG | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-05
Corporate Changes & Voting Matters
8-K · 2026-06-30
Corporate Changes & Voting Matters
8-K · 2026-06-22
Periodic Financial Reports
10-Q · 2026-05-07
Annual Report to Shareholders
ARS · 2026-04-29
Proxy Statements
DEF 14A · 2026-04-28
Proxy Statements
PRE 14A · 2026-04-15
Corporate Changes & Voting Matters
8-K · 2026-04-01
Headlines
Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia’s Rare Kidney Pipeline at ASN Kidney Week 2026
GlobeNewswire · 18h ago
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 5d ago
SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors
GlobeNewswire · 15d ago
SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development
GlobeNewswire · 22d ago
Akebia Therapeutics Doses First Patient in Phase 2 Ebribafusp Trial
MT Newswires · 23d ago
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases
GlobeNewswire · 23d ago
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 35d ago
Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston
GlobeNewswire · 36d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.